CommuniTake Remote Support Platform Delivers Clientless Remote iPhone Configuration
The new remote iPhone configuration helps boost support productivity and efficiency to reduce time and resources required to complete on-iPhone device deployments
CommuniTake Technologies has announced today that its Remote Support application is now providing clientless remote configuration for iPhone and iPad devices. Building on CommuniTake's commitment to simplify the support of Smartphones, the remote iPhone and iPad configuration radically changes iOS device support processes. The new solution provides support representatives with the ability to remotely define complex iOS device settings such as Email (POP3/IMAP & SMTP), Exchange Server, APN configurations and Wi-Fi.
Clientless remote iPhone configuration delivers customer value
CommuniTake's new solution provides greater flexibility in serving customers and drives increased support productivity through improved support representative practices: the support representative fills in the required profile fields and sends an SMS to the target iPhone. The new profile is automatically downloaded to the iPhone once the device holder opens the embedded link via secure access. Multiple configurations can be defined through one profile and the support representative can select a procedure from an extensive definitions library.
The new solution provides comprehensive and efficient device management processes that successfully provision and manage device utilization. Being a clientless solution, it enables rapid time-to-market across support operations.
The solution streamlines the changing needs of support representatives, allows higher customer satisfaction and reduces the needs of customers to reach points of service.
Supporting quotes
"We are focused on optimizing customer service and operational efficiency at the multi-channel support level. The clientless remote iPhone configuration extends our market-leading product’s capabilities," says Ronen Sasson, CommuniTake Technologies CEO.
"With this capability, service providers can capitalize on the operational advantages of running a remote support instance across their customer touch points. The user-friendly, Web-based application also enables enterprise IT personnel, in any location, to maintain, update and change devices logic without the need for external support professionals. It significantly intensifies the use of the enterprise devices across the daily tasks of enterprise professionals."
About CommuniTake Technologies Ltd.
CommuniTake Technologies was formed in 2009 and is privately held. The company is currently running several pilots with European tier 1 operators, a leading solution implementer and a prominent device manufacturer. CommuniTake Technologies has also sold its remote support platform to major operators and corporations in Israel. CommuniTake is the world's first to pre-install remote support on commercial AndroidTM devices and the world's best in market coverage across mobile OSs and devices. Recently, CommuniTake won RIM's 2010 EMEA innovation award for service excellence and it was selected by SFR (France) to be part of its prestigious young talent start-ups program. For additional information please visit the company's website www.communitake.com .
Trademarks
iPhone and iPad are trademarks of Apple Inc., registered in the U.S. and other countries.
Android is a trademark of Google Inc. Use of this trademark is subject to Google Permissions.
Contact:
CommuniTake Technologies Ltd.
Noam Potter, +972.545.515516
noam@communitake.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom